Related Experiment Videos
[Evaluation of diosmectite in acute diarrhea in children]
Insights
Diosmectite, an anti-diarrheal agent, showed no significant clinical differences in acute infantile diarrhea compared to oral rehydration solution (ORS) alone. However, parents reported higher satisfaction with Diosmectite treatment, and it slightly reduced hospitalization duration.
Area of Science:
- Pediatrics
- Gastroenterology
- Pharmacology
Background:
- Acute infantile diarrhea is a common pediatric condition requiring effective and safe treatment.
- Oral rehydration solution (ORS) is the standard of care, but adjunct therapies are explored to improve outcomes.
- Diosmectite is a natural clay with adsorbent properties, investigated for its potential in managing diarrhea.
Purpose of the Study:
- To evaluate the clinical efficacy, safety, and parental satisfaction of Diosmectite as an adjunct to ORS in acute infantile diarrhea.
- To compare treatment outcomes between children receiving ORS plus Diosmectite and those receiving ORS alone.
Main Methods:
- A case-control study involving 35 children aged 0-5 years with acute diarrhea.
- Children received either ORS plus Diosmectite (16 cases) or ORS alone (19 controls) for at least 5 days.
- Clinical parameters (liquid intake, weight recovery, fever, vomiting, stool frequency) and parental satisfaction were assessed.
Main Results:
- No significant differences were observed in clinical parameters between the Diosmectite-treated group and the control group within the first 48 hours.
- Diosmectite was well-tolerated, with no major adverse events reported.
- Parental satisfaction was higher in the Diosmectite group, though not statistically significant.
- A modest reduction in mean hospitalization duration (0.4 days) was noted in the Diosmectite group.
Conclusions:
- Diosmectite, when used with ORS, appears safe and well-tolerated in acute infantile diarrhea.
- While not demonstrating significant clinical superiority in key parameters, it may offer benefits in parental satisfaction and potentially reduce hospital stay.
- Further research with larger cohorts and potentially higher dosages is warranted to confirm these findings.
Abstract:
The aim of this case-control study, was to estimate clinical effects, safety and parents' assessment of Diosmectite, in acute infantile diarrhoea. Thirty-five children aged 0-5 years, with acute diarrhoea from at least 5 days received alternatively oral rehydration solution (ORS) and Diosmectite (3 g/day for 3 days in children aged under 3 years and 6 g/day for 3 days in children aged over 3 years) (16 cases) or ORS only (19 cases). At discharge, parents' opinion concerning satisfaction for treatment received was evaluated through a questionnaire. Differences in the amount of liquid intake, weigh recovery, resolution of fever, resolution of vomiting and number of loose stools in the first 48 hours of hospitalization were not significant. Diosmectite was well tolerated and no major side effects were found. Parents' satisfaction for therapy resulted higher in the treated group than in the control group, even if differences were not significant. Treatment with ORS and Diosmectite allowed to shorten the mean duration of hospitalization by 0.4 days/children in the treatment group compared to the control group. Further studies with more cases and with higher does of the drug are necessary to confirm our results.